A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

Phase 1/2 Completed 63 enrolled BiondVax Pharmaceuticals ltd.

RandomizedParallel-groupSingle-blindPrevention

Summary

A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy volunteers.

Timeline

Start: 2009-06
Primary completion: 2009-10
Completion: 2009-11

Publications

Results Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. J Clin Immunol. 2012 Jun;32(3):595-603. doi: 10.1007/s10875-011-9632-5. Epub 2012 Feb 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Multimeric-001	Vaccine	125 ug	Intramuscular
Subject	Multimeric-001	Vaccine	250 ug	Intramuscular
Subject	Multimeric-001	Vaccine	500 ug	Intramuscular

Indications

No indication recorded.